Carisma Therapeutics Inc. (OTC : CARM) Stock

MWN-AI** Summary

MWN-AI** Analysis

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Description

Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company¿s lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company¿s second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies.

Quote

Last:	$0.0001
Change Percent:	0.0%
Open:	$0.0001
Close:	$0.0001
High:	$0.0001
Low:	$0.0001
Volume:	9,315
Last Trade Date Time:	06/05/2026 12:49:08 pm

Stock Data

Market Cap:	$1,682,172
Float:	30,135,994
Insiders Ownership:	N/A
Institutions:	19
Short Percent:	1291811%
Industry:	Biotechnology & Life Sciences
Sector:	Healthcare
Website:	www.carismatx.com
Country:	US
City:	Philadelphia